Last $6.73 USD
Change Today -0.07 / -1.03%
Volume 941.0K
DYAX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

dyax corp (DYAX) Snapshot

Open
$6.74
Previous Close
$6.80
Day High
$6.99
Day Low
$6.60
52 Week High
02/26/14 - $10.99
52 Week Low
05/9/13 - $2.26
Market Cap
905.7M
Average Volume 10 Days
1.9M
EPS TTM
$-0.27
Shares Outstanding
134.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYAX CORP (DYAX)

dyax corp (DYAX) Related Bloomberg News

View More Bloomberg News

dyax corp (DYAX) Related Businessweek News

No Related Businessweek News Found

dyax corp (DYAX) Details

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat HAE and other PKM disorders. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has agreements with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The company also has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

120 Employees
Last Reported Date: 03/3/14
Founded in 1989

dyax corp (DYAX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $615.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $508.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $444.0K
Executive Vice President and General Counsel
Total Annual Compensation: $360.0K
Consultant
Total Annual Compensation: $148.7K
Compensation as of Fiscal Year 2013.

dyax corp (DYAX) Key Developments

Dyax Corp. Appoints Todd Bazemore as Chief Commercial Officer

Dyax Corp. announced the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Mr. Bazemore will be responsible for leading Dyax's commercial organization which currently markets KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. Mr. Bazemore joins Dyax as a pharmaceutical executive with 20 years of leadership and commercial operating experience in sales, marketing and managed markets. He most recently served as Vice President, Managed Markets at Sunovion Pharmaceuticals Inc. (formerly Sepracor).

Dyax Corp. Receives FDA Approval for Expanded Indication of Angioedema Drug

Dyax Corp. announced that it has received FDA approval for an expanded indication of KALBITOR, a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema, or HAE, attacks, to include patients 12 years of age and older. With this approval, KALBITOR is the first and only subcutaneous therapy available to treat acute attacks of HAE in patients 12 years of age and older. KALBITOR is also the only therapy that is not purified from human plasma that has been approved to treat this patient group. The FDA approval of this label expansion for KALBITOR is supported by the results from two previously completed Phase III placebo-controlled clinical studies, known as EDEMA3 and EDEMA4 as well as the results of study DX-88/19, which was ongoing at the time of the original approval of KALBITOR. The efficacy and safety profile observed in pediatric patients 12 years of age and older is similar to the adult population. KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of HAE in patients 12 years of age and older. KALBITOR, which was discovered and developed by Dyax, was the first subcutaneous treatment available in the United States for treating acute HAE attacks. Anaphylaxis has been reported after administration of KALBITOR. Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and HAE.

Dyax Corp. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 02:20 PM

Dyax Corp. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 02:20 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Gustav A. Christensen, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $6.73 USD -0.07

DYAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $8.34 USD 0.00
BioInvent International AB kr2.93 SEK -0.03
Genmab A/S kr192.00 DKK +9.00
Pharming Group NV €0.53 EUR +0.063
XOMA Corp $4.21 USD -0.11
View Industry Companies
 

Industry Analysis

DYAX

Industry Average

Valuation DYAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.1x
Price/Book 31.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit www.dyax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.